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Legionnaires’ Disease Treatment
Jorge F. Velazco
Abstract
Legionnaires’ disease is an important cause of community-acquired pneumonia 
as well as hospital-acquired pneumonia. Legionella pneumophila is an important but 
uncommon respiratory pathogen with significant morbidity and mortality. Initially 
recognized as a fatal cause of pneumonia in the 1970s. Untreated Legionnaires’ 
disease conveys high mortality, therefore a prompt treatment with appropriate anti-
biotics is of extreme importance. Currently, therapeutic options include macrolides 
and fluoroquinolones mainly, that have an effective therapeutic profile. Potential 
issues of bacterial resistance have risen, but overall, this is not a significant limita-
tion of therapy. In addition, attempts to identify other cases related to the case will 
help find potential sources.
Keywords: Legionella pneumonia, Legionella pneumophila, Legionnaires’ disease, 
Legionellosis, antimicrobial therapy
1. Introduction
Legionella pneumophila is responsible for 90% of Legionnaires’ disease (LD) 
[1–3]. Legionella pneumonia, or LD has an increasing incidence, its mortality has 
progressively improved from 34% in 1980, to 12% in 1998, to 3.1% in 2010, however 
20–25% of patients require mechanical ventilation with a mortality rate as high 
as 25% [4]. It is believed that the evolution of antibiotic therapy has improved 
outcomes [4]. Legionella pneumonia may have an atypical presentation that will 
contribute to its underdiagnosing and under-reporting [5], majority of reported 
cases are due to Legionella pneumophila serotype-1 (80%), that may reflect the 
relatively wide availability of commercial kits to test for this specific serotype [5]. 
Legionella is an ubiquitous environmental intracellular Gram-negative bacteria, 
therefore antibiotics capable of penetrating phagocytic cells should be selected, 
then macrolides and quinolones have become the recommended therapies [6–8]. 
Risk factors associated with higher mortality rates are older age, smoking, chronic 
cardiopulmonary disease, diabetes, alcohol abuse, cancer and immunosuppression 
[9]. Appropriate antibiotic selection will drop mortality significantly, from 60–70% 
to 10–20% [2, 7, 10, 11].
2. Treatment
For years, macrolides, specifically erythromycin, has been the mainstay of 
therapy until the 1990s [4, 12], however with the emergence of newer macrolides 
and quinolones, the therapeutic selection has shifted, and now Azithromycin or 
Levofloxacin are considered the mainstay of LD treatment [12]. Beta-lactam and 
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aminoglycoside antibiotics are ineffective in the treatment of LD, then empiric 
therapy based on either macrolides or quinolones for initial moderate to severe 
pneumonia will be a reasonable approach [12–14].
Effective antibiotic therapy depends on the ability to concentrate in alveolar 
macrophages, and for these concentrations to be effective, it will need to range from 
10 to 30 times greater than serum concentrations [15] Fluoroquinolones are antimi-
crobials with concentration-dependent bactericidal activity [16].
In cases of severe LD, combination therapy has been advocated without evidence 
of superiority [12]. The incidence of LD as cause of severe pneumonia requir-
ing ICU admission has been reported as high as second most common behind 
Streptococcus pneumonia (17.8 versus 21.6%, respectively) [2, 13].
In a retrospective review of 3157 adult cases, from more than 400 U.S. 
 hospitals between 2008 and 2013, it was noted that quinolones alone were used 
in 28.8%, whereas azithromycin alone was used in 34% of patients, only 1.8% 
of patients received combination therapy (see Figure 1). Hence, the majority of 
patients with LD in the US are treated with azithromycin and/or quinolone [4]. 
No prospective randomized trial has compared outcomes of levofloxacin versus 
azithromycin [14].
2.1 Empiric therapy
The choice of empiric antibiotic therapy is based on the premise of providing 
optimal therapy, the epidemiological features of the probable agents, and an infer-
ence of the most likely pathogen [17].
The empirical coverage for Legionnaires’ disease is still a matter of debate, in 
view of low testing frequency that underscores poor emphasis on Legionella role 
in pneumonia [18]. The incidence of LD is higher in cases of severe pneumonia, 
hence patients admitted to an ICU setting should be tested and treated as potential 
Legionella pneumonia [17]. Historically empirical optimal monotherapy treatment 
has been based on doxycycline, a quinolone or azithromycin [19].
Figure 1. 
In-hospital treatment strategies for patients with Legionnaires’ disease. Adapted from Ref. [4].
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Respiratory fluoroquinolones are an effective empiric treatment for bacterial 
community-acquired pneumonia, used as monotherapy in the outpatient setting, 
and hospitalized patients, as a first-line or alternative agents; in addition to be used 
as combination therapy in the ICU setting [20]. Azithromycin has a comparable 
antibiotic profile to fluoroquinolones, in addition has a favorable safety profile, 
higher intracellular concentrations and longer post antibiotic effect [21].
In a prospective observational study of 3934 hospitalized patients by Viasus 
et al., performed in Spain at a tertiary teaching hospital between 1995 and 2010, 
214 (5.4%) patients were diagnosed with LD, and 24 patients (11.2% of the LD 
patients) received inappropriate empirical antibiotic therapy; among the other 
190 patients, 111 received levofloxacin, 74 patients received macrolides, and three 
combination of quinolones and macrolides, 1 doxycycline and 1 clindamycin [22] 
(Table 1).
2.2 Targeted therapy
Early, targeted therapy that covers LD has shown to improve overall outcomes [19].
The most frequently identified of LD is Legionella pneumophila serogroup 1 in 
80% of cases [23]. New diagnostic test had been added to the testing armamen-
tarium (urinary antigen and polymerase chain reaction). Empirical therapy should 
be replaced by targeted therapy as soon as Legionella has been identified [17].
Garcia-Vidal et al. reported an observational cohort in Spain of all patients 
admitted with community acquired pneumonia from 2000 to 2014, 446 patients 
were diagnosed with LD; 335 patients (75.1%) received appropriate initial therapy 
with either quinolones, macrolides, combination with rifampin, or combination 
macrolide and quinolones. Primary outcome was overall 30-day in-hospital mor-
tality. Thirty-six patients were excluded, 175 patients received levofloxacin, 177 
patients received azithromycin and 58 patients received clarithromycin, without 
statistical significant difference for in-hospital 30-day mortality between the 
cohorts [24].
Once LD has been diagnosed, some experts suggest combined therapy instead 
of monotherapy for severe pneumonia, although there is no solid evidence sup-
port it [13]. In a retrospective observational multicenter Spanish series of 779 ICU 
patients admitted to the ICU with severe pneumonia, 25 patients (3.2%) were found 
to have LD, and prescription of monotherapy versus combination therapy was not 
Mild disease ambulatory 
setting
Moderately severe disease Severe disease intensive care unit 
setting
Doxycycline 100 mg orally 
q12h × 14d
Doxycycline 200 mg IV 
q12h × 72h, then 100 mg IV 
q12h × 11d
Doxycycline 200 mg IV q12h × 14d
Levofloxacin 500 mg orally 
q24h × 14d
Moxifloxacin 400 mg IV 
q24h × 14d
Levofloxacin 500 mg IV q24h × 14d
Moxifloxacin 400 mg orally 
q24h × 14d
Tigecycline 200 mg 
IV x 1dose, then 100 mg IV 
q24h × 14d
Moxifloxacin 400 mg IV q24h × 14d
Azithromycin 500 mg 
orally × 1dose, then 250 mg 
orally q24h × 10d
TMP-SMX 5 mg/kg IV q6h × 14d or 
Rifampin 300 mg orally q12h × 14d, 
maybe used as a second drug
Adapted from Ref. [15].
Table 1. 
Empiric therapy for Legionnaires’ disease.
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protocolized, with ICU mortality as primary endpoint; it was found that there was 
no statistical significant difference of overall ICU mortality among both treatment 
groups; however if the severe pneumonia was associated to shock the difference 
became statistically significant [13].
2.3 Antibiotic selection and duration
There may be a role for a specific antibiotic choice based on severity of illness: 
need for intensive care unit (ICU) admission, need for invasive mechanical ven-
tilation [4]. Dose and route of antibiotic delivery will be dictated by the severity, 
level of consciousness, and gastrointestinal function integrity [12]. Most of the 
antibiotics are available in oral presentations with excellent bioavailability (>90%), 
therefore transition among IV to oral regimens is seamless [19].
Despite absence of evidence, initial levofloxacin dose is recommended at 750 mg 
daily, and azithromycin 500 mg daily [14].
Levofloxacin use was associated with a shorter length of stay in the hospital, 
and shorter time to reach clinical stability [22]; moreover a small retrospective 
series showed no inferiority of ciprofloxacin to erythromycin in Japan [25]. In a 
retrospective single-center study at University of Michigan from 1999 to 2011, 
41 patients with LD were analyzed after been treated with azithromycin versus 
fluoroquinolones, comparing clinical outcomes: all-cause mortality, length of stay 
in the hospital, time to clinical stability and development of complications, showing 
no significant differences among the two therapies [19, 21] (Table 2).
Duration of therapy is important to provide cure and prevent relapse [19]. 
The Infectious Diseases Society of America/American Thoracic Society (IDSA/
ATS) recommend that patients with LD to be treated for 5–14 days, shorter courses 
maybe appropriate if Azithromycin is the antibiotic of choice. Treatment should not 
be stopped until patients are afebrile for 48–72 hours [22].
Therapy Normal adult dose Comments
Macrolides Azithromycin 500 mg IV q24h or clarithromycin 
500 mg IV q12h
Preferred regimen 
in most settings, or a 
fluoroquinolone
Fluoroquinolones Levofloxacin 500 mg IV q24h or moxifloxacin 
400 mg IV q24h
Generally well tolerated and 
effective
Rifampin 300–600 mg IV q12h Multiple drug interactions, 
including warfarin, opiates, 
cyclosporine, antiretroviral 
protease inhibitors; 
used with a macrolide or 
quinolone
Doxycycline 200 mg IV × 1dose, then 100 mg IV q12h Limited clinical experience 
shows activity
Combinations Levofloxacin 500 mg IV q24h or another 
fluoroquinolone + azithromycin 500 mg IV 
q24h; consider adding rifampin to monotherapy
No clear evidence of 
efficacy of combination 
therapy compared with 
monotherapy; often used 
in severe extensive disease 
in high-risk patients falling 
monotherapy
Adapted from Ref. [19].
Table 2. 
Therapeutic options for severe Legionnaires’ disease.
5Legionnaires’ Disease Treatment
DOI: http://dx.doi.org/10.5772/intechopen.88471
Immunocompromised patients have a higher incidence of LD; cavitation, 
empyema, extrapulmonary disease may occur; and urinary antigen is less sensi-
tive. In this population an antibiotic combination, and longer course maybe 
indicated (21 days) [3], and despite this this population has a higher mortality rate 
than matched groups [26]. An extended course up to 21 days is recommended for 
immunocompromised patients, severe disease, extrapulmonary manifestations, 
and inappropriate initial therapy [14].
Combination therapy has included different regimens: rifampin-clarithromycin; 
clarithromycin-ciprofloxacin-rifampin, and clarithromycin-levofloxacin-rifampin [13].
Older macrolides will interact with drugs like tacrolimus and ciclosporin 
through the cytochrome P-450 enzyme system, then quinolones, doxycycline or 
azithromycin maybe used in transplanted hosts [14].
2.4 Therapy outcome
Early initiation of appropriate antibiotics, improves outcomes, therapy with 
quinolones within 8 hours of ICU admission reduces mortality [5, 19].
In the Viasus’ Spanish series, 41 (19.1%) patients with LD developed severe dis-
ease (ICU admission or death), independent factors were identified in this group: 
current/former smoker, macrolide use, initial inappropriate antibiotic therapy 
and high risk pneumonia severity index (PSI) class. The overall cure rate is 95% at 
10–14 days after therapy [22] (Table 3).
In a Portuguese observational series, it was noted that patient with severe LD 
complicated by refractory respiratory failure were able to be supported by extra 
corporeal membrane oxygenation (ECMO) with high survival rates (86%); those 
patients had a faster clinical deterioration with very early ECMO initiation [27]. In 
a retrospective case review from University of Michigan between 1994 and 2006, 
survival rates were also noted to be high (67%) [28].
Antibiotic resistance is always a concern, it was noted that acquired resistance to 
macrolides, fluoroquinolones or rifampin could be easily selected in vitro; however 
in clinical practice, antibiotic susceptibility testing is not commonly performed 
[29], due to the fact that Legionella pneumophila serogroup 1 strains did not show 
any in vitro resistance towards eight antibiotics tested by Vandewalle-Capo et al. 
Therapy and outcome L. pneumophila 
pneumonia (n = 214)
S. pneumonia 
pneumonia (n = 1346)
P
Inappropriate antibiotic therapy 24 (11.2) 8 (0.6) <0.001
In-hospital complications 74 (34.6) 460 (34.3) 0.92
ICU admission 38 (17.8) 151 (11.2) 0.007
Need for mechanical ventilation 26 (12.4) 122 (9.2) 0.14
Time to clinical stability, median 
(IQR), d
3.5 (2–5) 4 (2–6) 0.85
Length of hospital stay, median 
(IQR), d
9 (6–13) 8 (6–12) 0.14
Length of intravenous therapy, 
median (IQR), d
4 (2–6) 5 (3–7) <0.001
In-hospital case-fatality rate 13 (6.1) 103 (7.8) 0.38
Adapted from Ref. [22].
Table 3. 
Therapy and outcomes of patients with L. pneumophila and S. pneumoniae pneumonia.
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(ciprofloxacin, moxifloxacin, levofloxacin, azithromycin, erythromycin, clarithro-
mycin, rifampin and doxycycline) [1].
In a systematic review and meta-analysis comparing quinolones versus macro-
lides effectiveness against LD, non-significant difference was found, however all 
studied outcomes favored quinolones, like mortality, clinical cure, time to fever 
resolution, length of stay in the hospital. Twelve studies were included in the analy-
sis, and the absence of significance maybe related to lack of statistical power [30].
3. Conclusion
Legionnaires’ disease is a relative frequent cause of pneumonia syndromes, and 
it is associated to high morbidity and mortality [22], therefore a delay in starting 
appropriate therapy has been associated with increased mortality [17]. Consistent 
with current guidelines, antibiotic therapy should be based on either azithromycin 
or a quinolone to treat for Legionella pneumonia. Optimum therapy is not properly 
supported by clinical evidence, however in view of rare potential bacterial resis-
tance to macrolides and quinolones, these antibiotic groups remain as mainstay of 
LD therapy.
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